Literature DB >> 12359603

Corticosteroids and central serous chorioretinopathy.

Cynthia A Carvalho-Recchia1, Lawrence A Yannuzzi, Silvana Negrão, Richard F Spaide, K Bailey Freund, Hanna Rodriguez-Coleman, Marcio Lenharo, Tomohiro Iida.   

Abstract

PURPOSE: The purpose of this study is to investigate the relationship between corticosteroid use and central serous chorioretinopathy (CSC).
DESIGN: A prospective, case-controlled study. PARTICIPANTS AND CONTROLS: A consecutive series of patients with acute manifestations of CSC and a control group matched for age, race, and gender were recruited between January 2000 and July 2000.
METHODS: A detailed clinical history was taken, and fundus examination with slit-lamp biomicroscopy was performed on all patients. Fluorescein angiography was obtained on the study patients.
RESULTS: A total of 50 patients was recruited. Twenty-six patients (52%) had a history of exogenous steroid use, including oral, intravenous, intranasal, and intraarticular administration. Two additional patients had a history of endogenous hypercortisolism (Cushing's syndrome). In a matched control group, eight patients (18%) had a history of steroid use. The difference in corticosteroid exposure between study patients and controls was statistically significant (P < 0.0001). MAIN OUTCOME MEASURES: History of corticosteroid use or Cushing's syndrome.
CONCLUSIONS: This study is consistent with previous reports associating steroid use with CSC. It identifies corticosteroids as a significant risk factor for the development of acute, exudative macular manifestation and implicates hypercortisolism as a factor in the pathogenesis of this disorder. Several forms of corticosteroid administration were observed to be a risk factor for CSC. Accordingly, susceptible patients in need of corticosteroids should be advised of the risk of developing acute manifestations of CSC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359603     DOI: 10.1016/s0161-6420(02)01117-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  82 in total

1.  Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy.

Authors:  M J Koss; I Beger; F H Koch
Journal:  Eye (Lond)       Date:  2011-11-11       Impact factor: 3.775

2.  Central serous chorioretinopathy.

Authors:  J M Jumper
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

3.  [Experiences with chronic central serous chorioretinopathy treated with half-dose photodynamic therapy and verteporfin].

Authors:  M Töteberg-Harms; M Kurz-Levin; J Fleischhauer; R Windisch
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

4.  Response of central serous chorioretinopathy evaluated by multimodal retinal imaging.

Authors:  R Sacconi; G Baldin; A Carnevali; L Querques; A Rabiolo; G Marchini; F Bandello; G Querques
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

5.  [Central serous chorioretinopathy--retinal function and morphology: microperimetry and optical coherence tomography].

Authors:  C Springer; H E Völcker; K Rohrschneider
Journal:  Ophthalmologe       Date:  2006-09       Impact factor: 1.059

6.  En face enhanced-depth swept-source optical coherence tomography features of chronic central serous chorioretinopathy.

Authors:  Daniela Ferrara; Kathrin J Mohler; Nadia Waheed; Mehreen Adhi; Jonathan J Liu; Ireneusz Grulkowski; Martin F Kraus; Caroline Baumal; Joachim Hornegger; James G Fujimoto; Jay S Duker
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

7.  Viagra-associated serous macular detachment.

Authors:  Polly Quiram; Sean Dumars; Bobbie Parwar; David Sarraf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

Review 8.  Retinal Diseases that Can Masquerade as Neurological Causes of Vision Loss.

Authors:  Tanyatuth Padungkiatsagul; Loh-Shan Leung; Heather E Moss
Journal:  Curr Neurol Neurosci Rep       Date:  2020-09-15       Impact factor: 5.081

9.  Improved thickness measurement method for choroidal hyperpermeability in central serous chorioretinopathy.

Authors:  Xing-Wang Chen; Fang-Yuan Han; Gang Su; Le Pan; Shan-Jun Cai
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

10.  Smokestack leak in central serous chorioretinopathy.

Authors:  Dhiren Bujarborua; Pran N Nagpal; Manab Deka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-15       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.